8-K: Vaxart Announces Q1 2025 Results and Business Update: COVID-19 Trial Resumes, Norovirus Program Advances

Vaxart reports Q1 2025 financial results, highlights the resumption of its COVID-19 Phase 2b trial, progress in its norovirus vaccine program, and a new CFO appointment.

Summary

• Vaxart announced its Q1 2025 financial results and provided a business update.
• The stop work order for the 10,000 participant portion of the COVID-19 Phase 2b trial has been lifted, and screening has commenced with dosing expected in Q2 2025.
• Enrollment is complete for the Phase 1 clinical trial evaluating the company's second-generation oral norovirus vaccine constructs, with topline data expected in mid-2025.
• A new avian influenza vaccine candidate demonstrated 100% protection in a ferret challenge model, compared to 0% survival in the placebo group.
• Jeroen Grasman has been appointed as Chief Financial Officer, effective May 19, 2025.
• The company's cash, cash equivalents, and investments totaled $41.9 million as of March 31, 2025, providing a cash runway into 2026.
• Q1 2025 revenue was $20.9 million, compared to $2.2 million in Q1 2024, primarily due to government contracts.
• The net loss for Q1 2025 was $15.6 million, compared to a net loss of $24.4 million for Q1 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the resumption of the COVID-19 trial, progress in other vaccine programs, and improved financial results compared to the previous year. However, the company still faces financial challenges and regulatory risks.

Positives

• The resumption of the COVID-19 Phase 2b trial is a significant positive development.
• Progress in the norovirus vaccine program, with Phase 1 trial enrollment completed, is encouraging.
• The promising preclinical data for the avian influenza vaccine candidate is a positive sign.
• The appointment of a seasoned financial executive as CFO could strengthen the company's financial management.
• The increased revenue in Q1 2025, driven by government contracts, is a positive indicator.
• The reduced net loss in Q1 2025 compared to Q1 2024 suggests improved financial performance.

Negatives

• The company is still operating at a net loss of $15.6 million for the quarter.
• The company's cash runway only extends into the first quarter of 2026, requiring further funding strategies.
• Phillip Lee is resigning as Chief Financial Officer for personal reasons.

Risks

• Clinical trial data may be subject to differing interpretations by regulatory authorities.
• Regulatory authorities may not be satisfied with the design and results from the clinical studies.
• The COVID-19 Phase 2b trial could be suspended or terminated.
• Vaxart's product candidates may not be approved by the FDA or non-U.S. regulatory authorities.
• Even if approved, Vaxart's product candidates may not achieve broad market acceptance.
• Vaxart may experience manufacturing issues and delays.
• Vaxart may not be able to obtain sufficient capital to fund its operations.

Future Outlook

Vaxart intends to continue managing costs prudently to deliver on upcoming clinical and regulatory milestones. The company is also exploring strategies to extend its cash runway through business development partnerships and non-dilutive funding options.

Management Comments

• We are pleased that the stop work order was lifted for the 10,000 participant portion of our COVID-19 Phase 2b trial and have immediately proceeded to begin screening participants, said Steven Lo, Chief Executive Officer of Vaxart.
• We appreciate the U.S. Department of Health and Human Services thorough review of our Phase 2b trial and robust body of data of our oral pill vaccine platform, which we believe can provide both mucosal and systemic immunity against common viral diseases safely and effectively.
• Going forward, we intend to continue to manage our costs prudently to deliver on our upcoming clinical and regulatory milestones, added Mr. Lo.

Industry Context

Vaxart is operating in a competitive vaccine development landscape, focusing on oral vaccine delivery technology. The progress in COVID-19, norovirus, and influenza programs positions the company to potentially address significant unmet needs in infectious disease prevention.

Comparison to Industry Standards

• Vaxart's oral vaccine platform differentiates it from traditional injectable vaccines, potentially offering advantages in terms of ease of administration and distribution.
• Companies like Moderna and Pfizer have focused on mRNA vaccines for COVID-19, while Vaxart is pursuing an oral pill vaccine.
• In the norovirus vaccine space, Vaxart is competing with companies like Takeda, which are developing traditional injectable vaccines.
• The 100% protection rate in the ferret challenge model for the avian influenza vaccine is a promising result compared to existing influenza vaccines.

Management Changes

Stakeholder Impact

• Shareholders may benefit from the progress in vaccine development and potential revenue generation.
• Employees will be involved in the execution of clinical trials and other research activities.
• Customers (potential vaccine recipients) may benefit from access to new and improved vaccines.
• Suppliers and creditors may be impacted by Vaxart's financial performance and ability to meet its obligations.

Next Steps

• Continue screening participants and begin dosing in the COVID-19 Phase 2b trial in Q2 2025.
• Report topline data from the Phase 1 norovirus vaccine trial in mid-2025.
• Publish the results of the preclinical avian influenza studies in a peer-reviewed forum.
• Explore business development partnerships and non-dilutive funding options to extend the cash runway.

Key Dates

Keywords

Vaxart, Vaccine, Clinical Trial, COVID-19, Norovirus, Influenza, Financial Results, Phase 2b, Phase 1, CFO